Skip to main content

Open Access The Effect of Rosmarinic Acid on Immunological and Neurological Systems: A Basic Science and Clinical Review

Download Article:
 Download
(HTML 67.8 kb)
 
or
 Download
(PDF 627.3 kb)
 
Rosmarinic acid (RosA) is an ester of caffeic acid and 3,4-dihydroxyphenylactic acid. RosA has a number of beneficial biological activities, including antiviral, antibacterial, anti-inflammatory, and antioxidant properties. Oxidative stress is recognized as a common factor in many neurodegenerative diseases and is a proposed mechanism for age-related degenerative processes as a whole. RosA has shown antioxidative action, acting as a scavenger of free radicals. RosA protects neurons from oxidative stress, significantly attenuated hydrogen peroxide-induced reactive oxygen species generation, and apoptotic cell death and could contribute at least in part to neuroprotective effects. RosA has also been shown to suppress immunoglobulin responses and inflammatory responses of polymorphonuclear leukocytes which may explain its effectiveness at treating seasonal allergic rhinoconjuctivitis in human clinical trials. The anti-inflammatory effects of RosA along with its immunomodulatory effects may also make it a novel agent for the treatment of auto-immune disorders. This review is focused on the effect of RosA on both immunological and neurological systems and its potential as a novel therapeutic agent for the treatment of associated conditions, especially those in which oxidative stress is a factor.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Allergy; Alzheimer’s disease; Anti-inflammatory; Antioxidant; Neurologic; Rosmarinic acid

Document Type: Research Article

Publication date: 01 December 2015

More about this publication?
  • JRM is a peer-reviewed medical journal published annually by AARM. It publishes original research, reviews, and editorials that contribute to the understanding of nutritional and botanical influence on underlying mechanisms of chronic illness. The journal was established by Michaël Friedman, ND as the founding editor. The journal's current editor-in-chief is Liz Sutherland, ND of National University of Natural Medicine.
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Terms & Conditions
  • Certification Exam
  • CME conferences
  • CME webinars
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more